Several clinicopathologic features of HER2-positive breast cancer patients were found to be associated with response to neoadjuvant therapy in a new study.
A 21-gene assay is effective in guiding the use of adjuvant chemotherapy in patients with early breast cancer.
A new study found artificial intelligence-based diagnostics could help with better diagnoses for upper gastrointestinal cancers.
Laparoscopy-assisted distal gastrectomy offered better short-term, post-surgical outcomes for patients with locally advanced gastric cancer who were undergoing neoadjuvant chemotherapy.
The addition of apalutamide to androgen deprivation therapy is well tolerated and significantly improves survival while maintaining health-related quality of life in men with prostate cancer.
The addition of the PARP inhibitor veliparib to carboplatin and paclitaxel offered significant improvement to patients with HER2-negative breast cancer.
Hyperbaric oxygen therapy can relieve symptoms of late radiation cystitis in patients who underwent radiotherapy of the pelvic region for prostate cancer.
The findings of a trial presented at ESMO 2019 may be a breakthrough when it comes to molecularly targeted treatment for prostate cancer.
The findings of a new study presented at ESMO may offer a new treatment for non–small cell lung cancer.
A phase III study found that adding 2 years of ovarian function suppression to tamoxifen extended disease-free survival in certain patients with hormone receptor–positive breast cancer.